Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Chimeric antigen receptor (CAR)-T cells have emerged as a promising treatment modality
for various hematologic and solid malignancies over the past decade. Animal models …

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent
form where there is minimal transcription or protein expression. Latently infected cells are a …

BACKGROUND Chimeric antigen receptor (CAR) T cells have emerged as an approach to
treat malignant tumors. This strategy has also been proposed for the treatment of HIV-1 …

HIV-specific chimeric antigen receptor–T cell (CAR T cell) therapies are candidates to
functionally cure HIV infection in people with HIV (PWH) by eliminating reactivated HIV …

Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly
expressed on memory T cells and enriched in latently HIV-infected CD4+ T cells. We …

Background CAR-T cell therapy is effective in the treatment of certain hematological
malignancies, and the expansion and functional persistence of CAR-T cells in vivo are …

During chronic human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV)
infection prior to AIDS progression, the vast majority of viral replication is concentrated within …

Although genome editing technologies have the potential to revolutionize the way we treat
human diseases, barriers to successful clinical implementation remain. Increasingly …

Chimeric antigen receptor (CAR) technology is having a huge impact in the blood
malignancy field and is becoming a well-established therapy for many types of leukaemia. In …